Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV

abstract
 

Highlights

• •Residual disease after debulking surgery is a significant prognostic parameter in FIGO stage IV epithelial ovarian and fallopian cancer.
• •Largest survival benefit is detected for patients with complete tumor resection, followed by patients with residual disease of 1-10mm.
• •No survival difference was detected between patients with residual disease of >10mm after cytoreduction compared to patients having no surgery.

Objective

To determine the impact of debulking surgery (DS) and residual disease (RD) on outcome in patients with FIGO stage IV epithelial ovarian cancer (EOC).

Patients and methods

This exploratory study included 326 consecutive patients with FIGO IV EOC treated in our centers from 2000 to 2014. Data were extracted from our prospectively maintained registry.